Scarica l'app Stockscreener
30.33
0.79%
-0.24
Dopo l'orario di chiusura:
30.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$30.57
Aprire:
$30.17
Volume 24 ore:
1.88M
Relative Volume:
1.19
Capitalizzazione di mercato:
$2.89B
Reddito:
$305.00K
Utile/perdita netta:
$-328.98M
Rapporto P/E:
-7.111
EPS:
-4.2652
Flusso di cassa netto:
$-309.60M
1 W Prestazione:
-2.54%
1M Prestazione:
-4.86%
6M Prestazione:
+88.97%
1 anno Prestazione:
+58.38%
Intervallo 1D:
$29.63
$30.68
Intervallo di 1 settimana:
$28.96
$31.54
Portata 52W:
$9.90
$34.04
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta VRDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
30.33 | 2.92B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Reiterato | Wedbush | Outperform |
| 2025-12-03 | Iniziato | William Blair | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - ulpravda.ru
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - ulpravda.ru
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Why CHRO stock attracts strong analyst attention - ulpravda.ru
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - ulpravda.ru
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - ulpravda.ru
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - ulpravda.ru
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price Target | VRDN Stock News - GuruFocus
Why Viridian Therapeutics Inc. stock remains resilientHigh Beta Stocks & Outstanding Portfolio Tips - ulpravda.ru
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment - Investing.com Canada
Jefferies reiterates Buy rating on Viridian Therapeutic stock with $44 target - Investing.com Canada
Viridian Therapeutic stock a Top Pick at TD Cowen ahead of busy 2026 - Investing.com Canada
Viridian Therapeutics Prepares for Transformational 2026 - BioSpace
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Exploring a Potential 36.59% Upside in the Biotech Arena - DirectorsTalk Interviews
Entry Recap: Will Viridian Therapeutics Inc. stock outperform international peersMarket Volume Report & Consistent Profit Trading Strategies - ulpravda.ru
Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan
What to keep an eye on in 2026 - Eyes On Eyecare
What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Viridian Therapeutics Earnings Notes - Trefis
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail
VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com
Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus
FDA grants priority review for Viridian’s thyroid eye disease drug - Investing.com
Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com
Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
Will Viridian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Retail & High Win Rate Trade Tips - Улправда
Published on: 2025-12-20 23:42:03 - Улправда
FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN) - Sahm
Aug Action: How geopolitical tensions affect Viridian Therapeutics Inc. stock2025 Support & Resistance & Community Verified Trade Signals - Улправда
Why Viridian Therapeutics Inc. (1S1) stock gets analyst attentionMarket Trend Summary & Weekly Breakout Watchlists - DonanımHaber
Published on: 2025-12-19 16:37:51 - Улправда
Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Fed Watch: Will Viridian Therapeutics Inc. stock attract more institutional investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock By Investing.com - Investing.com Canada
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):